Congo vs Mali: Tuberculosis patients living with HIV receiving antiretroviral therapy
Congo
621 patients
in 2021
Mali
518 patients
in 2021
Congo rank
45th
Mali rank
48th
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Congo
- Mali
How they compare
Congo currently reports 621 patients against 518 patients in Mali, a difference of 103 patients.
That makes Congo's figure about 1.2 times Mali's.
The two have swapped places 2 times across 14 shared years of data; in 2008 it was Congo ahead.
Congo ranks 45th and Mali ranks 48th of 183 countries.
Across the 3 decades both report, Congo averaged higher in 1 and Mali in 2.
Head to head by decade
| Decade | Congo | Mali | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 19 patients | 39 patients | 20 patients | Mali |
| 2010s | 190.2 patients | 394.1 patients | 203.9 patients | Mali |
| 2020s | 556 patients | 509.5 patients | 46.5 patients | Congo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Congo or Mali?
- Congo, at 621 patients against 518 patients in Mali as of 2021.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Congo and Mali?
- 103 patients, with Congo ahead.
- How many years of comparable data are there for Congo and Mali?
- 14 years are reported by both, from 2008 to 2021.
- How do Congo and Mali rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Congo ranks 45th and Mali ranks 48th of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.